Entrada Therapeutics (TRDA) EBIT Margin: 2023-2025
Historic EBIT Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to -2,915.18%.
- Entrada Therapeutics' EBIT Margin fell 280451.00% to -2,915.18% in Q3 2025 from the same period last year, while for Sep 2025 it was -197.59%, marking a year-over-year decrease of 22444.00%. This contributed to the annual value of 22.30% for FY2024, which is 2475.00% up from last year.
- Per Entrada Therapeutics' latest filing, its EBIT Margin stood at -2,915.18% for Q3 2025, which was down 21.34% from -2,402.51% recorded in Q2 2025.
- Over the past 5 years, Entrada Therapeutics' EBIT Margin peaked at 56.42% during Q2 2024, and registered a low of -2,915.18% during Q3 2025.
- Over the past 3 years, Entrada Therapeutics' median EBIT Margin value was -22.88% (recorded in 2023), while the average stood at -502.43%.
- In the last 5 years, Entrada Therapeutics' EBIT Margin surged by 14,612bps in 2024 and then crashed by 280,451bps in 2025.
- Quarterly analysis of 3 years shows Entrada Therapeutics' EBIT Margin stood at 11.72% in 2023, then tumbled by 2,741bps to -15.69% in 2024, then slumped by 280,451bps to -2,915.18% in 2025.
- Its EBIT Margin was -2,915.18% in Q3 2025, compared to -2,402.51% in Q2 2025 and -105.99% in Q1 2025.